Regulus Therapeutics (RGLS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

RGLS Regulus Therapeutics

Watchlist

1.6100
-0.0300-1.83%

Close Nov 29 13:00 ET

1.6200
+0.0100+0.62%

Post 17:02 ET

105.46MMarket Cap-1578P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

JonesTrading Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $8
Moomoo NewsNov 29 12:32 ET · Ratings
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
PR NewswireNov 26 08:00 ET
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsNov 12 08:31 ET · Ratings
Regulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy Rating
TipRanksNov 11 06:37 ET · Ratings
Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429
TipRanksNov 11 01:26 ET · Ratings
Regulus Therapeutics GAAP EPS of -$0.21 Misses by $0.04
Seeking AlphaNov 7 18:11 ET

Comments

Stock_Drift

Oct 24 15:16

After Hours Ticks. 4:15pm

$Visionary Holdings (GV.US)$ $Western Digital (WDC.US)$ $Integrated Media Technology (IMTE.US)$ $Deckers Outdoor (DECK.US)$ $MediaCo (MDIA.US)$ $Skechers USA (SKX.US)$ $Regulus Therapeutics (RGLS.US)$ $Abits (ABTS.US)$ $Spark I Acquisition Corporation (SPKL.US)$ $Tapestry (TPR.US)$ $Antelope Enterprise (AEHL.US)$ $Jeffs' Brands (JFBR.US)$ $Lyell Immunopharma (LYEL.US)$ $Smart Powerr (CREG.US)$ $Bionomics (BNOX.US)$
📊⚡️📊

Trytosaveabit

Oct 8 07:03

Update

$Regulus Therapeutics (RGLS.US)$ Regulus Therapeutics Inc: Remain on Track for an End of Phase 1 Meeting With FDA by End of 2024

Jaguar8

Oct 8 07:02

NEWS

$Regulus Therapeutics (RGLS.US)$
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)